The End of Injections? Entera Bio’s Oral Pill for Osteoporosis Gains Key Scientific Nod

TEL AVIV, Israel – August 04, 2026 – For decades, the most powerful treatments for severe osteoporosis have come with a significant catch: a needle. Patients seeking to actively rebuild bone, not just slow its loss, have had to commit to daily or monthly self-injections. Today, Israeli biotech firm Entera Bio Ltd. signaled that this paradigm may be on the verge of a dramatic shift. The company announced that new data from its Phase 2 trial for EB613, a once-daily oral tablet, has been selected for a prestigious Plenary Poster Session at the upcoming American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting. This high-profile recognition from the world’s leading bone research society suggests that a convenient, injection-free future for bone-building therapy is moving from a distant hope to a clinical reality.

A New Frontier in a Decades-Old Fight

Osteoporosis is a silent, progressive disease that weakens bones, making them fragile and susceptible to fractures. It's a colossal public health crisis, responsible for over two million fractures annually in the United States alone. For individuals over 50, the statistics are stark: one in three women and one in five men will suffer an osteoporosis-related fracture. These are not minor injuries; a hip fracture can be a life-altering event, with studies showing that up to 24% of patients die within a year. The economic toll is just as staggering, with the medical costs projected to balloon from $57 billion in 2018 to nearly $95 billion by 2040, driven by an aging population.

The treatment landscape has long been divided into two main camps. The first line of defense typically involves anti-resorptive agents, like the widely used bisphosphonates, which work by slowing down the cells that break down bone. While many of these are available as convenient oral pills, they primarily act as a brake on bone loss. For patients with severe osteoporosis and a high risk of fracture, a more aggressive approach is needed—one that actively builds new bone. These are the anabolic therapies.

Currently, this more potent class of drugs, which includes well-known treatments like Forteo® (teriparatide), is exclusively available via subcutaneous injection. This requirement creates a significant barrier to treatment. The burden of daily injections can lead to poor adherence, with many eligible patients forgoing the therapy altogether. “The best drug in the world is useless if the patient can’t or won’t take it,” noted one endocrinologist not affiliated with the study. “An effective oral anabolic would be a holy grail in osteoporosis management, fundamentally changing how we treat our highest-risk patients by dramatically improving the likelihood of long-term compliance.”

Decoding the Data: From Phase 2 to Plenary Stage

This is the critical gap Entera Bio aims to fill with EB613, an oral formulation of teriparatide, the same active peptide in the injectable Forteo®. The company’s proprietary N-Tab® technology is designed to shuttle large peptide molecules safely through the harsh environment of the stomach and into the bloodstream, a feat that has long challenged pharmaceutical science. The data earning the spotlight at ASBMR comes from a Phase 2 trial involving 161 postmenopausal women. The study successfully met its goals, demonstrating that EB613 increased crucial biomarkers of bone formation while simultaneously reducing markers of bone resorption. More importantly, it led to statistically significant increases in bone mineral density (BMD) in the lumbar spine, total hip, and femoral neck—key sites for debilitating fractures.

The presentation selected for the plenary session, however, goes a step further. It details a post-hoc analysis—a deeper dive into the data after the initial trial was completed—that specifically examined the drug’s effect on women with more severe disease, defined by a baseline T-score of -2.5 or lower. The abstract title promises "Markedly Enhanced Anabolic Effects" in this high-risk group. This targeted analysis is a savvy scientific and clinical move, suggesting that the drug's bone-building power is most pronounced in the very patients who need it most.

Selection for a Plenary Poster Session at the ASBMR Annual Meeting is no small feat. It is a competitive honor, with the program committee hand-picking abstracts they deem to be of the highest quality and impact from thousands of submissions. This serves as a powerful form of peer-reviewed validation, signaling to the broader scientific and medical communities that the data is robust and the findings are potentially transformative. It elevates the conversation around EB613 from a corporate press release to a topic of serious scientific discussion.

The Convenience Revolution: Patient Adherence and Market Disruption

If EB613 successfully navigates its final clinical hurdles, its impact could be twofold, touching both patient quality of life and market dynamics. For millions of patients, the prospect of swapping a daily injection for a daily tablet is revolutionary. This shift could dramatically lower the barrier to starting and, crucially, sticking with an anabolic therapy. Improved adherence translates directly into better clinical outcomes, meaning stronger bones and, ultimately, fewer devastating fractures. The psychological burden of managing a chronic disease is lessened when the treatment regimen is simplified, a factor that cannot be overstated in patient care.

From a business perspective, the implications are equally profound. The market for osteoporosis therapies is vast and growing. While dominated by generic oral anti-resorptives, the high-value anabolic segment is controlled by injectable products. An effective, safe, and convenient oral alternative could be a classic market disruptor. Entera Bio would not be competing on a level playing field; it would be offering a fundamentally different and more desirable product category. If approved, EB613 would be the first and only oral anabolic on the market, giving it a powerful first-mover advantage in capturing the segment of patients who are averse to or non-compliant with injections.

The Road Ahead for Entera Bio

This scientific validation comes at a pivotal moment for the clinical-stage company. Entera Bio is now preparing to launch a single, large-scale Phase 3 trial. This final study will enroll approximately 750 postmenopausal women with osteoporosis and is designed to provide the definitive evidence of efficacy and safety required for a New Drug Application (NDA) to the FDA. Such trials are complex, lengthy, and expensive, representing the most significant investment in a drug's development lifecycle. The positive reception at ASBMR could bolster investor confidence and aid in securing the substantial funding needed to see this crucial trial through to completion.

The success of EB613 would also serve as a powerful validation of Entera's underlying N-Tab® platform, which aims to convert other injectable peptide therapies—for conditions ranging from hypoparathyroidism to obesity—into oral tablets. For now, all eyes are on the upcoming ASBMR meeting in October and the subsequent launch of the Phase 3 trial. The journey from the lab to the pharmacy is long, but for the millions of women at risk of debilitating fractures, Entera Bio has just signaled that a simpler, injection-free path to stronger bones is clearly in sight.